Loading...
A randomized phase 2/3 study of naptumomab estafenatox + IFN-α vs IFN-α in renal cell carcinoma: final analysis with baseline biomarker subgroup and trend analysis
Hawkins, Robert E Gore, M Shparyk, Y Bondar, V Gladkov, O Ganev, T Harza, M Polenkov, S Bondarenko, I Karlov, P
Hawkins, Robert E
Gore, M
Shparyk, Y
Bondar, V
Gladkov, O
Ganev, T
Harza, M
Polenkov, S
Bondarenko, I
Karlov, P
Citations
Altmetric:
Abstract
To prospectively determine the efficacy of naptumomab estafenatox (Nap) + interferon α (IFN) versus IFN in metastatic renal cell carcinoma (RCC).
Affiliation
Description
Date
2016-02-05
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 924.28 KB
Keywords
Type
Article
Citation
A randomized phase 2/3 study of naptumomab estafenatox + IFN-α vs IFN-α in renal cell carcinoma: final analysis with baseline biomarker subgroup and trend analysis. 2016: Clin Cancer Res